Prepared by: Research Desk
Prepared by: Research Desk. Sources are linked for verification.
Sermorelin and tesamorelin are both synthetic analogues of growth hormone-releasing hormone (GHRH). GHRH is the hypothalamic peptide that signals the pituitary gland to release growth hormone. The two names often appear together, but the molecules differ in structure and U.S. regulatory history, and the research records cited on this page differ greatly in size. This page compares them on those points only. It does not rank them and contains no information on use.
Each molecule has its own full entry: Sermorelin: history, FDA status and the research record and Tesamorelin: an approved GHRH analogue, explained. This comparison focuses on where the two differ.
At a glance
Feature | Sermorelin | Tesamorelin |
|---|---|---|
Structure | GHRH(1–29): the first 29 amino acids of native GHRH [6] | Full-length GHRH(1–44) with an added chemical group at the N-terminus [3][5] |
Design aim | N-terminal fragment of GHRH that retains receptor activity [6][7] | Greater resistance to enzymatic breakdown than native GHRH [4][5] |
U.S. record | Drugs@FDA application 019863; product listed as discontinued [1] | Drugs@FDA application 022505; approved in 2010 [2][3] |
Approved use on record | No currently marketed approved product [1] | Reduction of excess abdominal fat in adults with HIV-associated lipodystrophy [3][4] |
Recent human evidence cited here | None of the sources on this page is a recent sermorelin trial; recent reviews address unapproved peptide use broadly [15][16] | Randomized phase 3 trials, secondary analyses and a 2026 meta-analysis [4][9][11] |
Anti-doping | GHRH and its analogues appear on the WADA Prohibited List [14] | Same category [14] |
Status checked 22 October 2026. For what each status label means, see Peptide FDA status explained.
Structure: a 29-residue fragment versus a modified 44-residue chain
Native human GHRH is a 44-amino-acid peptide. Research on GHRH analogues has long worked with the shorter N-terminal fragment, GHRH(1–29), because it keeps receptor activity [7]. Sermorelin is that fragment [6]. It is therefore a shorter peptide than the hormone it is modelled on. For background on how chain length shapes the vocabulary, see What are peptides?.
Tesamorelin keeps the full 44-residue sequence and adds a trans-3-hexenoyl group to the N-terminal tyrosine [3][5]. Reviews of tesamorelin describe this modification as a way to protect the N-terminus from cleavage by the enzyme dipeptidyl peptidase-4, which rapidly inactivates native GHRH in circulation [4][5].
A 2021 review of anti-doping detection methods covers synthetic GHRH analogues as a family. It describes the analytical approaches used to detect such modified sequences in biological samples [6].
Stability and half-life, as published
Reviews of tesamorelin describe native GHRH as rapidly inactivated in circulation by dipeptidyl peptidase-4 [4][5]. Later analogue design largely set out to address this short persistence. Researchers explored several routes:
N-terminal modification is the route used for tesamorelin [3][5].
PEGylation attaches polyethylene glycol chains to GHRH analogues. A 2003 review summarizes how this approach was studied as a way to extend their persistence in the body [7].
Albumin binding was used in CJC-1295, a separate long-acting GHRH analogue. A 2006 study in healthy adults reported prolonged growth hormone and IGF-I elevation after administration [8].
Published half-life figures for these molecules vary with study design and formulation, so this page does not quote a single number. The sources support a qualitative point: tesamorelin was engineered for greater stability than native GHRH, while sermorelin is an unmodified fragment [4][5][6]. The peptide glossary defines terms such as half-life, analogue and secretagogue.
Not every GHRH analogue is designed to activate the receptor. A 2022 study described the synthesis of GHRH antagonists, which block the same receptor. These compounds were reported to show antitumor and anti-inflammatory activity [18]. They are a separate research line from both molecules compared here.
Regulatory history in the United States
Sermorelin. Drugs@FDA lists sermorelin acetate under application 019863 and shows the product as discontinued [1]. No approved sermorelin product is currently marketed.
Tesamorelin. Drugs@FDA lists tesamorelin acetate under application 022505 [2]. It was approved in 2010 for the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. This is a specific and narrow indication [3][4][5]. The approval covers that product and that use only.
Compounding. The FDA publishes the categories of bulk drug substances that have been nominated for use in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act [12]. Its Pharmacy Compounding Advisory Committee considers nominated substances in public meetings [13]. A substance's appearance in those records describes its compounding review status. It is not an FDA approval. These statuses change, so the FDA pages are the place to check the current position.
What the main studies measured
Tesamorelin
The tesamorelin record is built around randomized, placebo-controlled trials in adults with HIV-associated abdominal fat accumulation. Reviews published after approval describe two phase 3 trials. Their primary measure was the change in visceral adipose tissue, assessed by computed tomography (CT) [4][5]. Secondary measures included trunk fat, lipid and glucose markers, IGF-I levels and adverse events [4][5].
Later work examined narrower questions:
Fat quality (2021). A secondary analysis of trial data used CT fat density as a marker of adipose tissue quality. It reported changes in density that were not explained by changes in fat quantity alone [9].
Integrase inhibitor regimens (2024). A study in AIDS examined efficacy and safety outcomes in people with HIV whose antiretroviral regimens included integrase inhibitors [10].
Meta-analysis (2026). A meta-analysis of randomized controlled trials pooled body composition, hepatic fat, metabolic and safety outcomes [11].
All of these studies concern one population defined by HIV status. They do not test other uses.
Sermorelin
None of the sources cited on this page is a recent clinical trial of sermorelin. The Drugs@FDA record documents its past approval and current discontinued status [1], and the detection literature covers it as one of the synthetic GHRH analogues [6]. Recent reviews instead look at the wider category of peptides used outside approved indications:
A 2026 review in Sports Medicine examines the safety and efficacy evidence for approved and unapproved peptides used for musculoskeletal injuries and athletic performance [16].
A 2026 orthopaedic review discusses applications, challenges and evidence gaps for therapeutic peptides in general [17].
A 2026 critical review of peptide use in recreational and professional sport and bodybuilding describes how such compounds circulate outside regulated channels [15].
These reviews summarize the gap between the approved and unapproved categories. They do not add new trial data. For how to weigh reviews against randomized trials, see How to read peptide research.
Anti-doping listing
The World Anti-Doping Agency's Prohibited List includes growth hormone-releasing hormone and its analogues among the prohibited peptide hormones [14]. Both sermorelin and tesamorelin fall in that class. Laboratory methods for detecting synthetic GHRH analogues in athlete samples are an active research area [6]. The current list year and wording are published on the WADA page itself.
Summary of differences
Structure: Sermorelin is the unmodified 1–29 fragment. Tesamorelin is the full 1–44 chain with an N-terminal modification.
Design: Tesamorelin's modification targets enzymatic stability. Sermorelin has no such modification.
Status: Sermorelin's approved product is discontinued. Tesamorelin has a current approval for one HIV-associated indication.
Evidence: Tesamorelin has randomized phase 3 data and a 2026 meta-analysis in its indicated population. None of the sources cited here is a recent sermorelin trial, and recent literature addresses unapproved peptide use more broadly.
Anti-doping: Both sit in the same WADA category.
Further reading
Readers who want the underlying science rather than summaries often turn to textbooks. Four criteria are the most useful when comparing books on hormone chemistry and endocrinology:
Accuracy and currency: Check the publication year and whether a newer edition exists, because endocrine pharmacology changes quickly.
Sourcing: Look for chapters that cite primary literature.
Depth: Introductory texts explain hormone axes. Advanced texts cover receptor pharmacology and analogue design, ideally with structure diagrams.
Format and price: Print, e-book and used copies vary widely in price. Look at the table of contents before buying.
A standard university endocrinology text is usually the strongest single reference for how hypothalamic hormones control the pituitary. A biochemistry or medicinal chemistry text adds the chemistry of how chains are modified for stability.
Library copies and older editions remain useful for the foundations, because the basic physiology of the axis has been stable for decades.
The graded reading list of science books applies these criteria to specific titles. The About page describes affiliate arrangements and how the site is funded.
Frequently asked questions
What is the main structural difference between sermorelin and tesamorelin?
Sermorelin is GHRH(1–29), the first 29 amino acids of the native hormone [6]. Tesamorelin is the full 44-amino-acid sequence with a trans-3-hexenoyl group added at the N-terminus [3][5].
Is either molecule FDA approved?
Tesamorelin has a current U.S. approval for reducing excess abdominal fat in adults with HIV-associated lipodystrophy [2][4]. Sermorelin was approved in the past, but Drugs@FDA lists its product as discontinued [1].
Why does tesamorelin have more trial data?
Tesamorelin went through randomized phase 3 trials before its 2010 approval, followed by secondary analyses and a 2026 meta-analysis [4][9][11]. Drugs@FDA lists sermorelin's product as discontinued [1], and none of the sources cited on this page is a recent sermorelin trial; recent reviews address unapproved peptide use broadly [15][16].
Are sermorelin and tesamorelin on the WADA Prohibited List?
The WADA Prohibited List includes GHRH and its analogues, a category that covers both molecules [14]. The current year's list is published on the WADA site.
Related on this site
Last updated: 22 October 2026.
Not medical advice. This page reports published research and regulatory records for information only.
Research-only notice: Content on this site is provided for research and educational purposes only and is not intended for human use. It is not medical advice.
Translation notice: Some content on this site may have been machine-translated using Google Translate and may contain errors.